Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
- 1 November 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 35 (9) , 702-710
Abstract
Changes in the biomarkers of host suppressor immune response were evaluated in patients with melanoma enrolled in 2 trials. Two similar cohorts of patients participating in the 2 studies were evaluated. The first (IFN/treme) tested interferon (IFN)-α2b and tremelimumab in metastatic melanoma and reported a response rate of 24%, 6.4 months median progression-free survival, and 21 months median overall survival. The second [toll-like receptor 9 (TLR)/GM] tested vaccination with MART-1, gp100, tyrosinase given with TLR-9 agonist and granulocyte-macrophage colony-stimulating factor and reported 9% response rate, median progression-free survival of 1.9 months, and median overall survival of 13.4 months. We monitored circulating T regulatory cells (T-reg) and myeloid-derived suppressor cells (MDSC) utilizing multicolor flow cytometry. In “IFN/treme,” changes in circulating T-reg and MDSC were compared between baseline, day 29 (end of IFN-α induction) and day 85 (1 course). The CD4+CD25hi+CD39+ T-reg percentage was increased most at day 85 (P=0.018) and less significantly at day 29 (P=0.09). There was a decrease in the percentage of MDSC populations taken in aggregate, which was most significant for monocytic MDSC (HLA-DR+ low/CD14+) at day 29 (PP=0.001). In “TLR-9/GM,” changes in T-reg and MDSC were compared between baseline and day 50 (4 vaccinations) and day 90 (8 vaccinations). There were no significant changes in T-reg or MDSC, except for a trend towards decreased (HLA-DR+ low/CD14+) MDSC at day 50 (P=0.07). Therefore, IFN/treme significantly downregulated MDSC suggesting a role on the significant clinical activity observed in this trial. T-reg findings suggest that IFN/treme induced clinically significant antitumor responses by inhibiting CTLA4 suppressive effects on T effectors, and less so by affecting T-reg.Keywords
This publication has 54 references indexed in Scilit:
- Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic MelanomaJournal of Immunotherapy, 2012
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV MelanomaJournal of Clinical Oncology, 2012
- Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patientsCancer Immunology, Immunotherapy, 2011
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 2004
- Derangement of immune responses by myeloid suppressor cellsCancer Immunology, Immunotherapy, 2003
- Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancerInternational Journal of Cancer, 1996
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsNew England Journal of Medicine, 1988
- Vitiligo in patients with metastatic melanoma: A good prognostic signJournal of the American Academy of Dermatology, 1983
- INCREASED EXPRESSION OF HUMAN MONOCYTE HLA-DR ANTIGENS AND FC-GAMMA RECEPTORS IN RESPONSE TO HUMAN INTERFERON INVIVO1983